Skip to main content

Jazz seizure drug receives FDA orphan status


PALO ALTO, Calif. The Food and Drug Administration has granted orphan drug status to Jazz Pharmaceuticals’ new drug candidate, JZP-8, which is used to treat recurrent acute repetitive seizures. The drug is designed to be a fast-acting intranasal spray for the treatment of recurrent acute repetitive seizures in patients with epilepsy.

ARS, also called seizure clusters, occurs in a small subset of patients with epilepsy who regularly experience breakthrough seizures in flurries or clusters despite treatment with a regimen of anti-epileptic drugs. ARS is a rare disorder, with an estimated prevalence in the U.S. of approximately 90,000 to 180,000 people.

In December 2007, Jazz Pharmaceuticals dosed the first patient in a Phase II clinical trial of JZP-8. “JZP-8 is one of the first development product candidates from our internal product identification and development program to enter Phase II,” said Samuel R. Saks, chief executive officer of Jazz Pharmaceuticals.

This ad will auto-close in 10 seconds